Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Review
Abstract
Tildrakizumab is a fully human monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). It has been approved for the treatment of adults with moderate-to-severe plaque psoriasis in several countries. The standard dose is 100 mg by subcutaneous injection at weeks 0 and 4, then every 12 weeks thereafter, although a 200 mg dosage at the same interval does have approval in some jurisdictions.
The aim of this article is to review the available evidence for tildrakizumab in treating moderate-to-severe chronic plaque psoriasis. In-depth discussion will be limited to pivotal studies and post hoc analyses.
References
Tildrakizumab (Ilumya) Product Monograph. US FDA.
Tildrakizumab (Ilumya) Product Monograph. EMA.
Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930-939.
Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276-288.
Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605-617.
Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. J Eur Acad Dermatol Venereol. 2019;33(6):1098-1106.
Menter A, Draelos Z, Heim J, Parno J, Mendelsohn A, Rozzo S, Griffiths C. Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/impact-of-body-weight-on-efficacy-of-tildrakizumab-in-moderate-to-severe-plaque-psoriasis/. Accessed September 12, 2020.
Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020;182(6):1359-1368.
Gordon KB, Reich K, Crowley JJ, et al. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. J Dermatol Treat. 2020. Online ahead of print.
Menter MA, Murakawa GJ, Glover H, et al. Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study. J Eur Acad Dermatol Venereol. 2020. Online ahead of print.
Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2020;82(2):519-522.
Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomised controlled trials. Br J Dermatol. 2018;179(3):615-622.
Gooderham M, Elewski BE, Pariser DM, et al. Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: letter to the editor. J Eur Acad Dermatol Venereol. 2019;33(10):e350-e352.
Bissonnette R, Fernandez-Penas P, Puig L, et al. Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. J Eur Acad Dermatol Venereol. 2020;34(1):e21-e24.
Haycraft K, DiRuggiero D, Rozzo SJ, Mendelsohn AM, Bhutani T. Outcomes of pregnancies from the tildrakizumab phase I-III clinical development programme. Br J Dermatol. 2020;183(1):184-186.
